title: A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.
abstract: We have studied 250 patients with mild to moderate essential hypertension (diastolic blood pressure 95-114 mmHg) and dyslipidaemia (high-density lipoprotein cholesterol (HDL-C) below 1.03 mmol.l-1, total cholesterol 5.17-9.05 mmol.l-1, and triglycerides 2.26-5.64 mmol.l-1) in a controlled double-blind, multicentre, parallel group trial. The patients took a fat-modified diet. After a 4-week placebo period, patients who continued to fulfil the selection criteria were randomly allocated to treatment with either carvedilol (a vasodilating beta-blocker) 25-50 mg o.d. (n = 116) or captopril (an ACE inhibitor) 25-50 mg o.d. (n = 117) for 6 months. In both groups there were favourable effects on the serum lipids. The relative changes (medians) in the carvedilol and captopril group were respectively: increase in HDL-C by 11% and 8%, decrease in total cholesterol by 11% and 10%, in low-density lipoprotein cholesterol by 16% and 12%, and in triglycerides by 13% and 14%. Equivalence of the two treatments was confirmed for the target variable change in HDL-C at a significance level of 5%. Reductions in supine systolic/diastolic blood pressures were comparable in the two groups (carvedilol: 23/19 mmHg, captopril: 20/18 mmHg). The improvement in lipid metabolism in patients treated with carvedilol is probably due to its alpha 1-blocking properties.
authors.affiliation: Department of Clinical Research, Boehringer Mannheim GmbH, Mannheim, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Hauf-Zachariou
authors.forename: L
authors.initials: L
authors.lastname: Widmann
authors.forename: B
authors.initials: B
authors.lastname: Zülsdorf
authors.forename: M
authors.initials: M
authors.lastname: Hennig
authors.forename: P D
authors.initials: PD
authors.lastname: Lang
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology*; D002227:Carbazoles / Q000494:pharmacology*; D000077261:Carvedilol; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
chemical_list: D000959:Antihypertensive Agents; D002227:Carbazoles; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008074:Lipoproteins; D011412:Propanolamines; D014280:Triglycerides; D000077261:Carvedilol; D002784:Cholesterol; D002216:Captopril